Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma.
about
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomideA comprehensive review of lenalidomide in B-cell non-Hodgkin lymphomaPossible biological and translational significance of mast cells density in colorectal cancerLenalidomide for the treatment of relapsed and refractory multiple myeloma.Practical approaches to the use of lenalidomide in multiple myeloma: a canadian consensus.Argonaute 2 promotes myeloma angiogenesis via microRNA dysregulation.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathwaysMicrovesicles secreted from human multiple myeloma cells promote angiogenesis.Calycosin-7-O-β-D-glucoside promotes oxidative stress-induced cytoskeleton reorganization through integrin-linked kinase signaling pathway in vascular endothelial cellsInduction therapy and stem cell mobilization in patients with newly diagnosed multiple myeloma.CD4⁺ T cells play a crucial role for lenalidomide in vivo anti-tumor activity in murine multiple myeloma.Novel targeted treatment strategies for refractory chronic lymphocytic leukaemia.Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.Biological aspects of angiogenesis in multiple myeloma.Can we change the disease biology of multiple myeloma?Tanshinone II a protects against lipopolysaccharides-induced endothelial cell injury via Rho/Rho kinase pathway.Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.An update on the use of lenalidomide for the treatment of multiple myeloma.Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab.Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms.Stimulation of invariant natural killer T cells by α-Galactosylceramide activates the JAK-STAT pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma model.Role of Endothelial Cells and Fibroblasts in Multiple Myeloma Angiogenic Switch.Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.Angiogenesis in myeloproliferative neoplasms, new markers and future directions.The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.Erythropoietin is involved in the angiogenic potential of bone marrow macrophages in multiple myeloma.Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin® protein MP0250: a preclinical study.Targeting vasculogenesis to prevent progression in multiple myeloma.Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma.
P2860
Q24614147-337F1C9F-0556-4A6B-9074-4F53EBF97B36Q26738937-E6E1CA24-4C1A-4427-9A05-867465D34FB2Q27009040-54551157-3997-4FFA-AC81-60461FD785C1Q33403183-ACD0B543-CFF0-454F-98BF-95D20200D620Q33404007-694F356E-0E0E-408F-89B7-06E5687C92A8Q33939162-2D717AF2-6238-4C1A-8AB6-383CA0782F2AQ34253548-154550BF-7565-4E0E-A5BC-89734DB6FD26Q34773850-A94E79AE-FF10-4636-8EE1-F0B4F46BE62AQ34807860-ED5C76D4-E3B5-4BA1-BD2D-909B28FE7C15Q35077269-E185F259-67FD-4C40-BFD1-CC4A195CFDE4Q35766342-643F9CE2-52EA-4723-A012-D2FF4AC7418BQ36014687-301DA7C5-E25E-403F-9E85-980CEBCEF524Q36546548-67E4A4EC-6FAE-40A7-AA0B-9E660DFAFE8CQ36612602-D80B38C8-F23B-4874-A3DD-E765A4BB78D8Q36715966-3C57DCD1-32DA-4E7D-97B5-C5E8F4A0513DQ37956524-4764311D-AA8D-4206-A034-E76DBBF185C0Q38062038-3CD36140-2E7E-4B4E-824C-E506FBFBCE16Q38308463-118E6309-DB91-42E0-9366-F55898B33929Q38462720-D147093C-510B-4CD7-8240-957E5CEB5AF9Q38545607-833D6020-8CF7-4F22-B39E-65DAD39E0A59Q38661370-887BF59D-2C4E-45DB-A372-7D365221D9FFQ38795045-8FD1D8F4-DAAA-4119-AA8E-B5EDE542D9E1Q38964255-A375D266-4031-4828-827D-352E97F2D89CQ38970580-35B2B0D4-01D9-48ED-AEAC-A7FBA22A7B9DQ39305373-21D147CF-AF5B-45CA-B0C9-F18A6B651622Q42622713-780416DA-48AE-4D19-BAAB-067F08D98F51Q42923841-9D224216-3EEF-4E76-A448-44ADF21C088BQ44034165-F06C2A8F-A85F-4B7F-B617-919E726B1F24Q51732175-CB6B6F71-7251-44A9-8409-ED6BA2D0F340Q52885536-D22CD406-532F-42C2-A278-B188CB772B00Q54110134-89949B2D-F7A0-4A80-9A97-50F4EDEFC577
P2860
Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Lenalidomide restrains motilit ...... with active multiple myeloma.
@en
Lenalidomide restrains motilit ...... with active multiple myeloma.
@nl
type
label
Lenalidomide restrains motilit ...... with active multiple myeloma.
@en
Lenalidomide restrains motilit ...... with active multiple myeloma.
@nl
prefLabel
Lenalidomide restrains motilit ...... with active multiple myeloma.
@en
Lenalidomide restrains motilit ...... with active multiple myeloma.
@nl
P2093
P50
P1476
Lenalidomide restrains motilit ...... with active multiple myeloma.
@en
P2093
Addolorata M L Coluccia
Andrea Urbani
Angelo Vacca
Annunziata De Luisi
Antonio Basile
Arianna Ferrucci
Emanuela de Luca
Franco Dammacco
Giovanni Quarta
Girolamo Ranieri
P304
P356
10.1158/1078-0432.CCR-10-2381
P407
P577
2011-02-09T00:00:00Z